Monitoring of Enoxaparin Therapy

Mechanism of Action and Laboratory Monitoring

The American College of Chest Physicians recommends that enoxaparin primarily inhibits factor Xa with minimal direct effect on thrombin, which is why traditional clotting tests like ACT are not useful for monitoring 1, 2
Enoxaparin is a low molecular weight heparin with a mean molecular weight of 4,500 daltons, making most molecules too short to bridge antithrombin to thrombin, and exhibits high anti-factor Xa activity but only minimal activity against thrombin 1, 2
The selective mechanism of enoxaparin means it does not significantly prolong clotting times measured by ACT, aPTT, or PT, as recommended by the American College of Chest Physicians 1, 3

The National Comprehensive Cancer Network recommends that when monitoring is necessary, anti-factor Xa levels are the appropriate test, NOT ACT 1, 4
Anti-Xa levels should be measured 4 hours after subcutaneous administration, with a therapeutic target range of 0.5-1.0 IU/mL for twice-daily dosing, as recommended by the National Comprehensive Cancer Network 4
For once-daily dosing, the target range is 1.0-2.0 IU/mL, according to the National Comprehensive Cancer Network 4

If reversal of enoxaparin is needed due to bleeding, protamine sulfate provides only partial neutralization, neutralizing approximately 60% of anti-Xa activity of LMWH, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 1, 3
The recommended dose is 1 mg protamine per 100 anti-Xa units, up to a maximum of 50 mg, with a second dose of 0.5 mg protamine per 100 anti-Xa units if bleeding continues, according to the American College of Chest Physicians 1, 3

The American College of Chest Physicians recommends against using enoxaparina for therapeutic systemic anticoagulation in patients on hemodialysis due to the significant risk of bleeding 5, 6, 7
For patients on hemodialysis who require anticoagulation of the extracorporeal circuit, the recommended dose of enoxaparina is 50-100 UI/kg (0.5-1.0 mg/kg) as a single bolus at the start of the dialysis session, with a median recommended dose of 70 UI/kg for 4-hour sessions 7
The American College of Chest Physicians recommends using unfractionated heparin (UFH) as the preferred alternative for therapeutic systemic anticoagulation in patients on hemodialysis, with a dose of 60 UI/kg IV bolus (maximum 4000 U) followed by an infusion of 12 UI/kg/h (maximum 1000 U/h) 5, 6, 7

The use of enoxaparina for therapeutic systemic anticoagulation in patients on hemodialysis is associated with a increased risk of bleeding, with a risk ratio of 3.88 (95% CI 1.78-8.45) 5, 6
The American College of Chest Physicians recommends against using fondaparinux in patients with a creatinine clearance <30 mL/min due to the risk of accumulation and increased risk of bleeding 8, 7, 9

For patients on enoxaparina for anticoagulation of the extracorporeal circuit, no routine monitoring of anti-Xa levels is required 7
For patients on enoxaparina for therapeutic systemic anticoagulation, monitoring of peak anti-Xa levels 4 hours after administration is recommended, with a target therapeutic range of 0.5-1.0 UI/mL 7, 9